
No. 18/2023 - CeMat obtains the legal title to land plot
Nasdaq Copenhagen
Nikolaj Plads 6
DK-1067 Copenhagen K
Copenhagen, 1 November 2023
ANNOUNCEMENT no. 18/2023
CeMat obtains the legal title to land plot
The CeMat Group has obtained a binding decision confirming the acquisition by law of the right of perpetual usufruct (RPU) to a developed plot of land on Wólczyńska Street, in the Bielany district of Warsaw. The area of the plot covered by the decision is of 13,033 sqm, with the right of perpetual usufruct established until 2089. This binding decision provides the legal basis for entering the right of perpetual usufruct (RPU) in the land and mortgage register.
The newly issued decision changes control of the plot from the right of possession to the right of perpetual usufruct. The final value of the property will be confirmed in an independent valuation.
Obtaining the legal title to the plot represents the important fulfilment of one of the company’s main goals for 2023, as well as its long-term goals reflected in its value creation chain.
According to the Group’s long-term goals, obtaining the legal title to the plot marks the first step in the value creation chain aimed at maximising the value of particular plots in Bielany, Warsaw. The value creation chain consists of obtaining the legal title to the plots, receiving a re-zoning decision for the land, obtaining the building permit, and then undertaking the pre-sale process and construction works.
This newly issued decision is the second such decision received in 2023, following a previous decision granting the company legal title to four road plots (covering 2,047 sqm) in March 2023.
The CeMat Group has control of the land through the right of possession to the site, the perpetual usufruct right and ownership rights. Part of the property holds the status of right of possession and is therefore not entered in the land and mortgage register. The area of land covered by the newly issued decision (13,033 sqm) represents 8,5% of the total land controlled by CeMat. The CeMat Group has the right of possession to 48% of the Warsaw property, the perpetual usufruct right to circa 51% of the property and the ownership right to circa 1% of the property.
The plot is well located on the same front building line of Wólczyńska Street as the ‘Moje Bielany’ residential project, construction of which started in August 2023. The plot has access to a public road and is not covered by the local Master Plan. Additional work is required to reclassify the land from its current service use to residential use. It is the intention of the CeMat Group to proceed with the next phase of the ‘Moje Bielany’ development project on the plot, in line with the company’s value creation chain.
Cemat A/S
Jaroslaw Lipinski
CEO
This announcement has been prepared in a Danish-language and an English-language
version. In case of doubt, the Danish version prevails.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Omkostningsreduktion på DKK ca. 45 mio.28.11.2023 13:32:23 CET | pressemeddelelse
Selskabsmeddelelse nr. 37/2023 Holbæk, den 28. november 2023 Omkostningsreduktion på DKK ca. 45 mio. Sparekassen Sjælland Fyn A/S har i dag gennemført en reduktion af medarbejderstaben med 29 (5 % af medarbejderstaben). 21 medarbejdere er fratrådt i dag, de øvrige 8 medarbejdere er kommende pensioneringer og stillingsbortfald. Herudover er der en række øvrige driftsomkostninger, som det er lykkedes at eliminere. Samlet set bremses de årlige omkostninger med DKK ca. 45 mio. (ca. 5 %) med fuld effekt fra 1. januar 2024. ”De gennemførte medarbejder- og omkostningsreduktioner er udtryk for, at sparekassen hele tiden arbejder med at trimme forholdet mellem indtægter og omkostninger ” udtaler adm. direktør Lars Petersson. ”Virkeligheden er, at aktivitetsniveauet – særligt på boligområdet – er langt lavere end de senere år. Herudover har vi hurtigere end forventet eksekveret på en lang række teknologiske effektiviseringer jf. vores strategi. Det betyder, at vi kan drive sparekassen mere effek
Changes in the number of own shares held by Aktia Bank Plc28.11.2023 13:00:00 CET | Press release
Aktia Bank Plc Stock Exchange Release 28 November 2023 at 2.00 p.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company's Board of Directors, divested a total of 808 own shares held by the company to four persons as a deferred payment based on the company’s remuneration programs. The divestment of own shares is based on the authorisation by the Annual General Meeting of Shareholders held on 5 April 2023. After the above-mentioned divestments, a total of 159,538 shares remain in the company’s possession. Aktia Bank Plc Further information: Mia Smeds, Communications director, +358 44 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Ltd Mass media www.aktia.com Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsink
Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning28.11.2023 13:00:00 CET | Pressemelding
Aktia Bank Abp Börsmeddelande 28.11.2023 kl. 14.00 Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning Aktia Bank Abp har idag med stöd av ett beslut av bolagets styrelse överlåtit totalt 808 Aktia-aktier i bolagets besittning till fyra personer som betalning av uppskjutna ersättningar enligt bolagets belöningssystem. Överlåtelsen av aktier är baserad på bemyndiganden av den ordinarie bolagsstämman 5.4.2023. Efter ovan nämnda överlåtelser har bolaget sammanlagt 159 538 aktier i sin besittning. Aktia Bank Abp Mera information: Mia Smeds, kommunikationsdirektör, tfn 044 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Oy Massmedier www.aktia.com Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjänster i ett flertal kanaler och ger personlig service på våra verksamhetsställen i huvudstadsregionen samt i Åbo-, Tammerfors-, V
Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas28.11.2023 12:44:51 CET | Pressemelding
STOCKHOLM, SVERIGE 28 november 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat positiva resultat från en studie med bolagets läkemedelskandidat golexanolone i en preklinisk modell av PBC-relaterad symtomologi och neuroinflammation. Resultaten indikerar en normaliserande effekt på kognitiva symtom såsom trötthet, motoriska störningar, neuroinflammation och neurala signaler. Resultaten publiceras i novemberutgåvan av den internationellt välrenommerade tidskriften Liver International. Resultaten från den prekliniska studien, som utfördes i en validerad och välkänd sjukdomsmodell av kolestas, visar att golexanolon förbättrar symtom som vanligtvis ses vid PBC. Studien visar en tydlig minskning av central trötthet, signifikanta förbättringar av korttidsminnet och normaliserande motoriska funktioner efter en 4-5 veckors lång behandling med golexanolon. ”Trötthet är högst prioriterat för symtomlindring för PBC-patienter e
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis28.11.2023 12:44:51 CET | Press release
STOCKHOLM, SWEDEN – November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented positive results from a study of the company’s drug candidate golexanolone in a preclinical model of PBC-like symptomology and neuroinflammation. The results indicate a normalizing effect on cognitive symptoms, such as fatigue, motor impairments, neuroinflammation, and neural signaling. The results are published in the November issue of the internationally renowned journal Liver International. The results from the preclinical study, which was performed in a validated and well-known disease model of cholestasis, show that golexanolone improves symptoms generally seen in PBC. The study shows a clear reduction in central fatigue, marked improvements in short-term memory, and normalized motoric functions following a 4–5-week treatment regimen with golexanolone. “Fatigue is the highest priority of symptom relief for PBC patient